Gritstone Oncology Inc (GRTS) is trading -5% lower at $3.55 today. Shares of the stock are moving less than other names in the space on what is turning out to be a slightly glum day for the Health Care sector.


Gritstone Oncology Inc has been trading between a 52-week high of $14.42 and a 52-week low of $1.71. The stock has a market cap of $258 Million.

Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies.

GRTS stock slips as Goldman cuts to sell on liquidity issues (NASDAQ:GRTS)
Seeking Alpha 08-22-22

Goldman Sachs Downgrades Gritstone Oncology to Sell
Investing.com 08-22-22

GRTS stock hits six-month high on publication of data for cancer vaccine (NASDAQ:GRTS)
Seeking Alpha 08-16-22

Gritstone bio Inc. (NASDAQ:GRTS) 4.41% Up Over Last Week, What Happens Next?
Marketing Sentinel 08-12-22

Gritstone bio Inc. (GRTS) CEO Andrew Allen on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha 08-06-22